Chapter 1. Research Objective
1.1 Objective, Definition & Scope
1.2 Methodology
1.2.1 Primary Research
1.2.2 Secondary Research
1.2.3 Market Forecast - Estimation & Approach
1.2.4 Assumptions & Assessments
1.3 Insights and Growth - Relevancy Mapping
1.3.1 FABRIC Platform
1.4 Data mining & efficiency
Chapter 2. Executive Summary
2.1 Irritable Bowel Syndrome Treatment Market Overview
2.2 Interconnectivity & Related markets
2.3 Ecosystem Map
2.4 Irritable Bowel Syndrome Treatment Market Business Segmentation
2.5 Irritable Bowel Syndrome Treatment Market Geographic Segmentation
2.6 Competition Outlook
2.7 Key Statistics
Chapter 3. Strategic Analysis
3.1 Irritable Bowel Syndrome Treatment Market Revenue Opportunities
3.2 Cost Optimization
3.3 Covid19 aftermath - Analyst view
3.4 Irritable Bowel Syndrome Treatment Market Digital Transformation
Chapter 4. Market Dynamics
4.1 DROC
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PEST Analysis
4.2.1 Political
4.2.2 Economic
4.2.3 Social
4.2.4 Technological
4.3 Market Impacting Trends
4.3.1 Positive Impact Trends
4.3.2 Adverse Impact Trends
4.4 Porter's 5-force Analysis
4.5 Market News - By Segments
4.5.1 Organic News
4.5.2 Inorganic News
Chapter 5. Market Segmentation
The Irritable Bowel Syndrome Treatment Market has been analysed to include the below segmentation:
By Type
• IBS with Diarrhea (IBS-D)
• IBS with Constipation (IBS-C)
• Mixed IBS
By Product
• Rifaximin
• Eluxadoline
• Lubiprostone
• Linaclotide
• Others
By Distribution Channel
• Hospitals• pharmacies
• Drug Stores and Retail Pharmacies
• Online pharmacies
Chapter 5A. Regional Segmentation
The Irritable Bowel Syndrome Treatment Market has been analysed by studying the following regions:
North America
• By Type
• By Product
• By Distribution Channel
Europe
• By Type
• By Product
• By Distribution Channel
APAC
• By Type
• By Product
• By Distribution Channel
LatAm
• By Type
• By Product
• By Distribution Channel
MEA
• By Type
• By Product
• By Distribution Channel
**The Regions are further studied to analyse the major countries within the respective regions. The coverage of the country level data is dynamic and is updated regularly based on the market movements. Normally, the countries covered in the report include:
• North America - United States, Canada, Mexico;
• Europe - United Kingdom, France, Italy, Germany, Spain, Rest of Europe;
• Asia Pacific - China, India, Japan, South Korea, Rest of APAC;
• Middle East & Africa - South Africa, GCC Countries, Rest of MEA;
• Latin America - Brazil, Argentina, Rest of LatAm;
Chapter 6. Market Use case studies
Chapter 7. KOL Recommendations
Chapter 8. Investment Landscape
8.1 Irritable Bowel Syndrome Treatment Market Investment Analysis
8.2 Market M&A
8.3 Market Fund Raise & Other activity
Chapter 9. Irritable Bowel Syndrome Treatment Market - Competitive Intelligence
9.1 Company Positioning Analysis
9.1.1 Positioning - By Revenue
9.1.2 Positioning - By Business Score
9.1.3 Legacy Positioning
9.2 Competitive Strategy Analysis
9.2.1 Organic Strategies
9.2.2 Inorganic Strategies
Chapter 10. Key Company Profiles
*The Irritable Bowel Syndrome Treatment Market Report profiles companies based on the material impact they have on the market ecosystem. These are hence, to be read as 'Key Players' and not necessarily 'Market Leaders'.
Companies are typically profiled to include:
10.x.1 Company Fundamentals
10.x.2 Performance Overview
10.x.3 Product Overview
10.x.4 Recent Developments
Key Companies profiled in this report include:
• ABBOTT LABORATORIES
• ALLERGAN PLC
• ARDELYX INC.
• ASTELLAS PHARMA INC.
• ASTRAZENECA PLC
• JOHNSON & JOHNSON (MCNEIL CONSUMER HEALTHCARE)
• NOVARTIS AG
• SEBELA PHARMACEUTICALS INC.
• TAKEDA PHARMACEUTICAL COMPANY LTD.
Chapter 11. Appendix
11.1 About AllTheResearch (ATR)
11.2 ATR Services
11.3 Author details
11.4 Terms & Conditions
11.5 Contact us